Loxo@Lilly Oncology Medical @LoxoLillyOnc Twitter profile

Last Seen Profiles

@abunwaf090059

@ankarakulisi06

@vivrantny

@bigbvdr

@lo10lo10lo10lol

@chydabby055

@Spain_Kpop_

@palad_d_a

@schmidtemma01

@dhiego_jvg

@_mochipi23

@phsmatsfootball

@Ajscott816

@dest_yen

@maybssbm

@Tevitakuridrani

@DrTerranceLeon

@Gameforge

@Migerito1

@TheMrLillyShow

@remidios

@AQUAhydrate

@johijack

@MKGElementary

@vickypangeranb1

@Crypto_Priestt

@Judith4949

@SheepEndy

@TheNiftyNFTCo

@RateWork

@beachkatie

@kelleydeyo

@qliphoth2006100

@CG_CIMT

@ton05052019

@SrgtKillerSpark

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

Covalent BTK inhibition has provided a major advancement in treating B-cell malignancies, such as #CLL & #MCL . But #DYK : CLL & MCL can evolve over time to evade covalent inhibition, presenting a growing unmet need for patients. #LymSM #LeuSM Learn more:

7

37

159

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

10 months

Despite the clinical benefits of oral anticancer medications in B-cell malignancies, managing drug adherence remains a clinical challenge. #leusm #lymsm Learn about factors that influence adherence & how you can help your patients overcome these barriers:

4

13

141

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

See results from a real-world database study assessing patient characteristics, treatment patterns, & clinical outcomes in patients w/ previously treated Mantle cell #lymphoma . Published in Advances in Hematology: #lymsm #MCL #RealWorldEvidence

2

16

123

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

8 months

#ESMO23 - Dr. @jhaveri_komal presents results from the phase 1a/b EMBER study, investigating an oral #SERD with or without everolimus or alpelisib, in ER+, HER2- advanced #breastcancer . See the presentation details here: #bcsm #CancerResearch

1

17

133

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

New #lungcancer data from @SWOG published in @JCO_ASCO OS data from the phase II Lung-MAP sub-study S1800A, evaluating a #VEGFR2 inhibitor + a #PD1 inhibitor vs standard of care in advanced #NSCLC previously treated w/ IO and platinum chemotherapy: #LCSM

13

24

123

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

10 months

The androgen signaling pathway is a key driver of #prostatecancer progression in #mCRPC . The interaction between the androgen receptor (AR) & other molecular pathways leads to continued AR activation, resulting in disease progression. #pcsm Learn more:

24

16

122

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

8 months

#MantleCellLymphoma (MCL) is a rare & aggressive B-cell #lymphoma . Presentation, characteristics, & course are heterogenous, making disease mgmt complex. #lymsm HCPs - Learn how biomarkers & other prognostic factors can help optimize therapy & outcomes:

2

15

117

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

In honor of #ColorectalCancerAwarenessMonth , we're highlighting the importance of: 1) Regular screening - the most effective way to detect #CRC in earlier stages. 2) Biomarker testing at diagnosis - to inform treatment decisions & improve outcomes. #CRCsm #GetScreened

8

37

109

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

10 months

Invasive disease-free survival (IDFS) & distant relapse-free survival (DRFS) are standardized, clinically meaningful endpoints in #EarlyBreastCancer #ClinicalTrials . Learn more about these endpoints & their significance in adjuvant #breastcancer trials:

4

17

110

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

Mantle cell lymphoma ( #MCL ) is a rare form of non-Hodgkin #lymphoma w/ significant unmet needs, particularly for patients who’ve relapsed/progressed after initial therapies. #lymsm HCPs: Learn more about the challenges & unmet needs for pts living w/ MCL:

2

15

90

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

At #ASCO22 – @SWOG is presenting OS data from the Lung-MAP non-matched sub-study S1800A, evaluating a #VEGFR2 inhibitor + a #PD1 inhibitor vs standard of care in advanced #NSCLC previously treated w/ IO and platinum chemotherapy View presentation details:

4

10

81

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

8 months

#Breastcancer is a journey unique to each individual. Hear from Dr. Shaheenah Dawood about developing individualized therapy plans that account for patient specific factors, such as medication beliefs & family member involvement. #BCSM Learn more here:

2

17

82

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

For patients with HR+/HER2- early breast cancer, which feature(s) should be assessed to help determine the risk of disease recurrence? Check your knowledge by clicking the images below & visit for more information. #EarlyBreastCancer #BreastCancer #BCSM

7

6

83

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

10 months

CURRENTLY ENROLLING #ClinicalTrials : A phase 3, open-label, randomized study of our non-covalent (reversible) BTK inhibitor in patients w/ previously treated, BTKi naïve, #MantleCellLymphoma . View detailed trial & enrollment info here: #lymsm #lymphoma

10

12

80

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

7 months

#ASH23 - We’re excited to share new and updated data from our research in hematologic cancers, including three oral presentations, at the @ASH_hematology Annual Meeting in San Diego. Check out our full lineup of presentations here: #leusm #lymsm

4

9

78

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

7 months

Thank you to all those who joined us for an excellent #ESMO23 ! HCPs – You can visit the Loxo @Lilly congress hub to see the research we presented at this year's meeting, including new data in #breastcancer , as well as RET-driven cancers: #CancerResearch

2

6

74

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

HR+ HER2- #EarlyBreastCancer generally has a positive prognosis, however ~20% of cancers will progress to incurable metastatic disease. Click to learn more about the clinical & pathological factors associated with a higher risk of #recurrence : #BCSM

7

20

70

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) have been recently updated for B-Cell Lymphomas, including mantle cell #lymphoma (MCL). View the updated guidelines here: #lymsm #MCL #MantleCellLymphoma

1

14

64

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

We are proud to be part of @YaleCancer 's Consortium to Advance Equity in Early-Phase Clinical Trials This program will increase access for underrepresented & minority patients to investigational new drug therapies & reduce barriers to trial participation:

7

4

62

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

8 months

Hypothetical case: 52 y/o perimenopausal woman presents w/ right breast mass & is diagnosed w/ HR+/HER2- #EBC . Clinical workup shows stage III disease, 6.5cm tumor, histologic grade 3, & 4+ ALNs. #bcsm Is there a high risk of recurrence? Learn more here:

7

5

61

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

View the results from the largest cohort in monarchE, a phase 3 open label study of the addition of a CDK4 & 6 inhibitor to endocrine therapy in patients w/ HR+, HER2-, node-positive, high-risk #earlybreastcancer . Published in @OncJournal : #bcsm

3

12

57

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

We are excited to connect with the greatest minds in #CancerResearch from around the world at #AACR23 ! To view the full lineup of Loxo @Lilly presentations showcasing new clinical data from our early phase #oncology pipeline, click here:

6

2

61

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

9 months

Managing patients w/ #breastcancer requires multidisciplinary expertise from oncologists, nurses, pharmacists & others. As HCPs help patients navigate their #patientjourney , it is important to get the first treatment cycle right. Learn more here: #bcsm

5

8

61

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

The risk of recurrence in HR+ #EarlyBreastCancer shows a steep incline during the first 2 years after primary diagnosis. Click here to learn more about this patient group and methods to guide them through their treatment journey: #BCSM #EBC #BreastCancer

1

8

58

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

At #AACR23 , see Dr. @YoninaMG present the first clinical data from our phase 1 study of a KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors. #KRAS #CancerResearch View presentation details here:

2

6

55

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) have been recently updated for breast cancer, including updates in #earlybreastcancer . Visit to see the latest version (Guidelines➡️Tx by Cancer Type➡️Breast Cancer) #bcsm #breastcancer

2

10

56

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

11 months

HCPs - It is important for patients with HR+/HER2- early #breastcancer to quantitatively understand their risk of recurrence. #bcsm #ebc Learn more about methods to communicate those risks & how to help patients over the course of their treatment journey:

2

5

54

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

8 months

#ESMO23 Oral Presentation: A preplanned overall survival interim analysis from the monarchE trial, including 5-yr efficacy outcomes in HR+, HER2- #EarlyBreastCancer patients at high risk of recurrence. See the results here: #bcsm #breastcancer

4

10

53

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

Published in @TheLancetOncol : Read the 4-year results from a preplanned analysis from monarchE, a phase 3 study of the addition of a CDK4 & 6 inhibitor to endocrine therapy in patients w/ HR+, HER2-, node-positive, high-risk #earlybreastcancer : #bcsm

3

10

50

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

8 months

This #BloodCancerAwarenessMonth we're bringing attention to #MantleCellLymphoma , a rare form of non-Hodgkin #lymphoma w/ significant unmet needs. HCPs - Visit our #MedEd site for #MCL resources including disease overviews, adherence strategies, and more:

0

15

52

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

HCPs - For patients with HR+/HER2- #EarlyBreastCancer , clinical factors, such as ≥4 positive ALNs & stage III disease, are associated w/ a higher risk of recurrence. Understanding these factors can help optimize adjuvant therapy. #bcsm Learn more here:

0

9

50

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

11 months

Results from a phase I/II clinical trial evaluating an investigational non-covalent (reversible) BTK inhibitor for the treatment of #CLL have been published in @NEJM . Read the study results here: #lymsm #leusm #BTKi

2

10

51

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

HCPs: #DYK ~30% of patients with high-risk #EarlyBreastCancer will experience disease recurrence within 5 years? As health care providers, it is important to recognize high-risk features to optimize adjuvant therapy. #bcsm #breastcancer Learn more here:

3

12

52

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

Learn more at #AACR23 about our phase 1 study investigating an FGFR3 inhibitor in patients w/ FGFR3-altered advanced #urothelial carcinoma & other solid tumors. Trial in progress poster: #CancerResearch #ClinicalTrials

2

7

48

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

6 months

Quiz: More than half of patients with HR+/HER2- #MBC have at least one disease-related factor that is more likely to confer a poor prognosis. Check your knowledge by clicking the images below, then visit to learn more. #bcsm #breastcancer

6

9

49

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

At #ASCO22 , we’re announcing a new adjuvant trial called EMBER-4, studying our investigational SERD for patients with ER+, HER2- #earlybreastcancer who have an increased risk of recurrence. #BreastCancer #BCSM #ClinicalTrials

3

4

42

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

#AACR23 attendees - Thank you to everyone who joined us in Orlando & online! Visit the Loxo @Lilly congress hub to explore the research we presented at this year's meeting, including the first clinical data from our #KRAS G12C program: #CancerResearch

4

6

44

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

11 months

With ~30% of patients with high-risk, HR+/HER2- #EarlyBreastCancer experiencing disease recurrence within 5 years, invasive disease-free survival (IDFS) is a meaningful endpoint in EBC clinical trials. Want to learn more? Click here: #BreastCancer #BCSM

2

3

41

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

At #ASCO23 – Check out new findings from @CancerResrch ’s #ctMoniTR Project, investigating changes in #ctDNA levels as an early indicator of outcomes in advanced NSCLC treated w/ TKI. View presentation details here: #lcsm #nsclc

5

7

43

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

Hypothetical case: 50 y/o postmenopausal woman presents w/ right breast mass & is diagnosed w/ HR+/HER2- #EBC . Clinical workup shows stage II disease, 4 cm tumor, histologic grade 3, & 1+ ALN. Is there a high risk of recurrence? Take the quiz & learn more

3

4

41

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

#ASCO23 attendees - Thank you to everyone who joined us in Chicago & online! Visit the Loxo @Lilly congress hub to view the research we presented at this year's meeting, including updates in breast, hematologic, and pediatric cancers: #CancerResearch

1

5

42

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

A real-world study of US oncology practices quantifies the characteristics and outcomes of a high-risk HR+, HER2- #earlybreastcancer population, defined by the clinicopathologic criteria used in the #monarchE trial. #bcsm Published in @FutureOncol_FSG :

2

8

36

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

11 months

NOW PUBLISHED in @JCO_ASCO : Updated results from the phase I/II BRUIN study, investigating a highly selective, non-covalent (reversible) BTKi in patients w/ covalent BTKi pre-treated #MantleCellLymphoma . #lymsm Read the results here:

0

7

39

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

7 months

Evaluating risk of recurrence can help HCPs appropriately identify & treat pts w/ HR+/HER2- EBC & avoid overtreatment of those at low-risk of recurrence. (6/6) Want access to more EBC resources, including thought leader videos & infographics? Click here:

0

1

39

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

8 months

In @NEJM , see the interim results from LIBRETTO-531, a phase III study of a highly selective RET-kinase inhibitor vs. cabozantinib or vandetanib in advanced, kinase inhibitor naïve, RET-mutant #MedullaryThyroidCancer . See the results: #PrecisionMedicine

3

5

37

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

Published in @TheLancetOncol , learn more about tumor-agnostic efficacy & safety of a selective RET inhibitor in pts w/ RET fusion-positive solid tumors other than lung or thyroid. #CancerResearch View the results:

1

10

38

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

We look forward to sharing new research from across our #oncology pipeline at #AACR23 , including 2 oral presentations & 5 posters. Visit us onsite at the Loxo @Lilly booth (1043) to learn more or explore our virtual congress page here: #CancerResearch

1

2

37

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

Thank you to everyone who joined us in Chicago and online for the #ASCO22 Annual Meeting! Follow the link to visit the Loxo @Lilly virtual exhibit, where you can view our presentations and learn more about our latest research: #CancerResearch

0

4

34

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

Published in @JCO_ASCO , an updated assessment of the safety & efficacy of a selective RET inhibitor in pts w/ RET fusion–positive #NSCLC treated in the phase I/II LIBRETTO-001 trial. #lcsm Learn more:

1

6

34

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

8 months

At #ESMO23 – Learn about the impact of dose reductions on efficacy of a CDK 4 & 6 inhibitor for patients with high risk #EarlyBreastCancer . See the analysis from the monarchE study here: #CancerResearch #bcsm #breastcancer

1

35

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

A key question for #oncology providers is how #biomarkertesting can be improved & streamlined for greater patient access. To address this, we’ve partnered w/ organizations to find solutions to help overcome the barriers. Learn more about these programs:

4

34

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

8 months

We’re excited to be at #ESMO23 ! We look forward to sharing our latest research in RET-driven #NSCLC & #ThyroidCancer , as well as new data in #BreastCancer . Visit us onsite at the Loxo @Lilly medical booth (731) or click here to explore our congress hub:

1

4

34

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

At #AACR23 , check out our poster presentation exploring the unique pharmacodynamic properties conferred by differential binding to BTK between covalent BTK inhibitors & a non-covalent BTK inhibitor. #leusm #lymsm View the poster details here:

3

7

34

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

We're excited to be back in Chicago for #ASCO23 and look forward to sharing updates from our research in breast, hematologic, and pediatric cancers. Stop by the Loxo @Lilly booth (14007) or follow the link to explore our congress hub: #bcsm #leusm #lymsm

1

2

33

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

See results from a U.S. real-world database study assessing clinical outcomes in patients with CLL/SLL who previously received treatment with a covalent BTK inhibitor and BCL2 inhibitor. Published in Leukemia & Lymphoma: #lymsm #leusm #RealWorldEvidence

1

4

32

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

Join Dr. @ErikaHamilton9 as she presents efficacy & safety results by age from monarchE, a phase 3 study evaluating the addition of a CDK 4/6 inhibitor to ET in patients w/ HR+, HER2-, high-risk #earlybreastcancer . #bcsm #ASCO23 Oral Presentation:

1

32

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

8 months

#ESMO23 poster presentation – A preoperative window-of-opportunity study of an oral selective estrogen receptor degrader (SERD) in patients with ER+, HER2- #EarlyBreastCancer . Read the study results from the EMBER-2 study here: #bcsm #BreastCancer #SERD

0

2

31

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

Thank you to everyone who joined us in New Orleans for the #AACR22 Annual Meeting! As this year’s meeting comes to a close, please visit our virtual medical booth to view our presentations and learn about our latest oncology research: #CancerResearch

1

2

30

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

8 months

NOW PUBLISHED in @NEJM : Interim results from LIBRETTO-431, a phase 3 trial investigating front-line use of a selective RET inhibitor vs chemotherapy w/ or w/o pembrolizumab in RET fusion+ advanced #NSCLC . Read the results here: #PrecisionMedicine #LCSM

3

2

30

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

At this year's St. Gallen Breast Cancer Conference, we're presenting results from the monarchE trial, a study of HR+, HER2-, node-positive, #earlybreastcancer patients at high risk of recurrence. #SGBCC2023 #bcsm Check out the poster here:

0

2

29

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

At #ASCO22 we’re presenting the trial design of postMONARCH, an ongoing study in patients w/ metastatic HR+/HER2- #breastcancer that have progressed or recurred following the use of a CDK4 & 6i w/ endocrine therapy. View presentation details here: #bcsm

0

4

29

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

8 months

🎗 #ChildhoodCancerAwarenessMonth may be coming to an end, but the work to end #ChildhoodCancer never stops. At Loxo @Lilly , we're committed to advancing research & drug development to support these brave young patients. Let's conquer childhood cancer together!💪 #CCAM #GoGold 💛

1

2

30

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

8 months

At the AACR-NCI-EORTC Conference, we’re sharing the first preclinical data from our orally available pan-KRAS inhibitors with selectivity over HRAS and NRAS. See the presentation details here: #Targets23 #KRAS #CancerResearch

0

3

29

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

Now published in @JAMAOnc - Efficacy and safety from a pre-planned analysis of patients who received neoadjuvant chemotherapy in the #monarchE trial. #earlybreastcancer #bcsm View publication here:

0

8

25

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

At #ASCO23 , we're presenting a trial in progress for a phase 2 study evaluating the addition of a CDK 4/6 inhibitor to irinotecan + temozolomide in pediatric & adult patients w/ relapsed or refractory #EwingSarcoma . #clinicaltrials See the details here:

0

2

28

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

Attending #ASCO22 ? Join us for a presentation on the ongoing Phase I EMBER trial in patients with advanced breast cancer and endometrial endometrioid cancer who received our investigational SERD. View presentation details here: #breastcancer #bcsm

1

6

27

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

#AACR23 attendees - See results from the phase 1/2 BRUIN study, investigating a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation. #leusm #lymsm View the presentation details here:

1

3

27

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

Poster presentation at #EHA2023 – A comparison of bleeding-related events in patients who received a highly selective, non-covalent (reversible) BTK inhibitor with and without antithrombotic agents. #lymsm #leusm See the results here:

0

1

24

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

Thank you to everyone who joined us in Vienna and online for an exciting #EHA2022 ! Follow the link below to visit the Loxo @Lilly virtual exhibit, where you can view our presentations and learn about our latest #hematology research: #LeuSM #LymSM

1

3

26

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

8 months

Check out our oral presentation at #ESMO23 to learn about prognostic and predictive impact of estrogen/progesterone receptor and Ki-67 expression in pts w/ high-risk, HR+, HER2- early #breastcancer . #BCSM #EBC Exploratory analysis from the monarchE trial:

2

3

25

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

Join us at #ASCO22 , where we’ll be presenting on factors increasing the rate of treatment discontinuations in the monarchE trial. View presentation details here: #EarlyBreastCancer #BCSM

1

3

26

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

Watch Dr. Shaheenah Dawood discuss the challenge of adherence & strategies to help patients overcome these barriers. HCPs: Click here to access resources supporting adherence & persistence to oral medication in pts w/ breast cancer: #bcsm #breastcancer

5

1

26

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

At #EHA2023 - Learn about the genomic evolution & resistance to a highly selective, non-covalent (reversible) BTK inhibitor in patients with CLL that were previously treated with a covalent BTK inhibitor (cBTKi). #leusm #lymsm See the details here:

0

5

23

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

Aloha from #PPLC22 ! We are excited to join clinicians and researchers from around the globe to discuss the latest advances in patient care. Stop by exhibit 202 to meet our medical team and learn about the research we will be presenting at this year’s meeting. #LymSM #CLL #MCL

1

6

25

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

We're excited to join clinicians and researchers from around the globe at #WCLC22 in Vienna! Stop by exhibit booth 401 to meet our medical team and learn more about the work we are doing to improve the lives of people living w/ #LungCancer #LCSM

0

1

23

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

At #ASCO22 – New data from @TheUSONetwork ’s MYLUNG Consortium: Predictors of Biomarker Testing Among Patients with Metastatic Non–Small Cell Lung Cancer (mNSCLC). View presentation details here: #LCSM #NSCLC

0

2

22

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

8 months

We're presenting the first preclinical data from our orally available #KRASG12D inhibitor that is selective against wild-type #KRAS . Poster presentation at the AACR-NCI-EORTC Conference: #Targets23 #CancerResearch

0

24

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

#EHA2022 kicks off this week! We look forward to joining the #hematology community to discuss the latest advances in patient care. John Pagel, VP, & head of global hematology, served as a physician taking care of pts for 25 yrs. Hear what inspired him to join the Loxo @Lilly team

3

4

20

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

We're proud to present long-term patient-reported outcomes from monarchE, which investigated a CDK 4 & 6 inhibitor w/ endocrine therapy in pts w/ high-risk, HR+, HER2- #earlybreastcancer . View the #ESMOBreast23 presentation here: #bcsm #breastcancer

1

0

22

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

Lilly is committed to developing & delivering targeted treatments for people living with #LungCancer ICYMI: At #ELCC22 , we shared updated data from the LIBRETTO-001 trial of a selective RET inhibitor in patients w/ RET fusion-positive #NSCLC Learn more:

4

0

21

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

NOW ENROLLING: A phase 1a/b study of our investigational FGFR3 inhibitor. This is an open-label, multi-center, phase 1a/b study in patients w/ FGFR3-altered advanced #urothelial carcinoma & other solid tumors. #clinicaltrials Learn more here:

0

3

21

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

#EHA2023 poster presentation: Matching-adjusted indirect comparison of a highly selective, non-covalent (reversible) BTKi vs. venetoclax continuous monotherapy in pts w/ relapsed/refractory CLL previously treated w/ a covalent BTKi #leusm Learn more here:

0

4

19

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

We’re excited to share new data for hematologic cancers, including three oral presentations, at this year’s @ASH_hematology Annual Meeting in New Orleans. Learn more about our full lineup of presentations at #ASH22 here: #leusm #lymsm

1

2

20

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration non-covalent (reversible) BTKi + venetoclax & rituximab vs. venetoclax & rituximab in previously treated CLL/SLL. #leusm #lymsm View the #ASCO23 Trial in Progress poster:

0

2

20

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

Covalent BTK inhibition has transformed the mgmt of #CLL / #SLL , but many pts will require additional treatment. While at #PPLC22 , check out our poster presentation assessing a highly selective, reversible (non-covalent) #BTKi in previously treated CLL/SLL:

0

4

18

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

Interested in learning about our trial in progress examining a CDK 4/6 inhibitor combined w/ chemoimmunotherapy in pediatric & young adult patients w/ relapsed/refractory #neuroblastoma ? See the details here: #ASCO23 #clinicaltrials #PediatricTumors "

1

0

18

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

9 months

Increased adherence to adjuvant therapy in HR+ #EarlyBreastCancer has been associated w/ a decrease in all-cause mortality. #bcsm Strategies to improve adherence are centered around open & honest communication between the HCP & patient. Learn more here:

1

3

19

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

Updated results & subgroup analysis w/ 2yrs of survival follow-up from the phase 1/2 BRUIN study, investigating a non-covalent (reversible) #BTKi in patients w/ mantle cell #lymphoma previously treated w/ a covalent BTKi. #lymsm Presented at #ASCO23 :

1

2

18

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

At #EHA2022 , we’re presenting results from the BRUIN phase 1b study of a highly selective, reversible (non-covalent) #BTKi in combination w/ a #BCL2 inhibitor +/- immunotherapy for patients w/ relapsed/refractory #CLL . View presentation details here:

0

16

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

#AACR22 attendees, we’re excited to share results from the BRUIN phase 1b study evaluating a reversible (non-covalent) #BTKi in patients with relapsed/refractory chronic lymphocytic #leukemia #CLL . View the presentation details here:

1

0

18

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

#ESMOBreast23 – We are presenting results from a real-world UK study evaluating treatment patterns & clinical outcomes of a CDK 4 & 6 inhibitor in patients with HR+, HER2- metastatic breast cancer. See the details here: #bcsm #MBC #RealWorldEvidence

1

17

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

We’re excited to join the #hematology community in Houston for @SocietyofHemOnc ’s 10th annual meeting! #SOHO22 If attending, be sure to stop by booth 150 & meet our medical team. To learn more about our latest #bloodcancer research & pipeline, visit:

0

1

8

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

Join our poster discussion at #ASCO23 to learn about long-term safety with ≥ 12 months of a non-covalent (reversible) BTK inhibitor in patients with relapsed/refractory B-cell malignancies. #lymsm #leusm View the presentation here:

0

1

18

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

#PPLC22 attendees: We’re sharing updated results from the phase 1/2 BRUIN study, evaluating a highly selective, reversible (non-covalent) BTK inhibitor in previously treated mantle cell lymphoma. View poster presentation: #MCL #LymSM #BTKi

1

5

17

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

#ESMOBreast23 attendees - Interested in learning about the preclinical characterization of an oral selective estrogen receptor degrader (SERD) with activity in a brain metastasis model? See the details here: #bcsm #breastcancer #SERD

0

6

16

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

Trial in Progress at #ASCO23 : BRUIN CLL-314: A phase 3, open-label, randomized study of a non-covalent (reversible) BTKi vs. ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). #leusm #lymsm Learn more here:

0

2

16

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

We are excited to be at #ESMOBreast22 ! Stop by exhibit booth 27 to meet our medical team. Or, if attending online, visit our virtual exhibit to connect & learn about the research we’ll be presenting at this year’s meeting. Visit our virtual booth: #bcsm

0

3

16

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

1 year

See our poster presentation at the St. Gallen Breast Cancer Conference, describing real-world patient characteristics, treatment & long-term outcomes in pts w/ #earlybreastcancer at a high risk of recurrence in Scotland. #SGBCC2023 #bcsm View the poster:

0

3

14

Loxo@Lilly Oncology Medical

@LoxoLillyOnc

2 years

We’re looking forward to presenting new data from across our #oncology portfolio at the #ASCO22 Annual Meeting. Developing innovative new medicines for people living with #cancer is at the center of what we do. Learn more about our presentations here:

2

0

15